IL42154A - Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby - Google Patents

Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby

Info

Publication number
IL42154A
IL42154A IL42154A IL4215473A IL42154A IL 42154 A IL42154 A IL 42154A IL 42154 A IL42154 A IL 42154A IL 4215473 A IL4215473 A IL 4215473A IL 42154 A IL42154 A IL 42154A
Authority
IL
Israel
Prior art keywords
stereoisomeric
hydrogen
fluorine
acid
component
Prior art date
Application number
IL42154A
Other languages
English (en)
Other versions
IL42154A0 (en
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Publication of IL42154A0 publication Critical patent/IL42154A0/xx
Publication of IL42154A publication Critical patent/IL42154A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL42154A 1972-05-19 1973-05-01 Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby IL42154A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (de) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
IL42154A0 IL42154A0 (en) 1973-07-30
IL42154A true IL42154A (en) 1976-12-31

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
IL42154A IL42154A (en) 1972-05-19 1973-05-01 Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby

Country Status (17)

Country Link
US (1) US3928326A (de)
JP (1) JPS547794B2 (de)
BE (1) BE799728A (de)
CA (1) CA1003402A (de)
CY (1) CY1012A (de)
DE (1) DE2323216C3 (de)
DK (1) DK133249C (de)
FI (1) FI50711C (de)
FR (1) FR2185406B1 (de)
GB (1) GB1428416A (de)
HK (1) HK49079A (de)
IL (1) IL42154A (de)
KE (1) KE2969A (de)
NL (1) NL175917C (de)
SE (1) SE378110B (de)
SU (1) SU468408A3 (de)
ZA (1) ZA732956B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
HU221584B (hu) * 1993-01-08 2002-11-28 Aktiebolaget Astra Új vastagbél- (colon) vagy csípőbél- (ileum) specifikus, cukortartalmú szteroidszármazékok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
EP1663999A2 (de) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitoren der phosphodiesterase iv
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7750151B2 (en) 2004-04-09 2010-07-06 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2006305620A1 (en) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN101616901A (zh) * 2006-09-22 2009-12-30 兰贝克赛实验室有限公司 Iv型磷酸二酯酶的抑制剂
EP2066661A2 (de) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Phosphodiesteraseinhibitoren
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2007340129B2 (en) 2006-12-26 2012-02-02 Pharmacyclics Llc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
EP2109608B1 (de) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amidsubstituierte indazole als poly-(adp-ribose)-polymerase (parp)-hemmer
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
CN103497185A (zh) 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
EP3103791B1 (de) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino-derivate als histondeacetylase-hemmer
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (de) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Zusammensetzungen von Phosphodiesterase-IV-Hemmern
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
AU2010294598B2 (en) * 2009-09-11 2016-09-01 Chiesi Farmaceutici S.P.A. Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
CN108676800B (zh) 2010-08-17 2022-11-11 瑟纳治疗公司 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制
EP2608669B1 (de) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
ES2627820T3 (es) 2011-09-13 2017-07-31 Pharmacyclics, Inc. Formulaciones de inhibidor de histona desacetilasa en combinación con bendamustina y usos de las mismas
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
HUE040025T2 (hu) 2012-08-24 2019-02-28 Univ Texas A HIF aktivitás heterociklusos modulátorai betegség kezelésére
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (de) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Kreisförmige polynukleotide
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
EP3525785A4 (de) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. Kdm5-inhibitoren
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
MX2019013690A (es) 2017-05-18 2020-01-27 Regeneron Pharma Conjugados de farmaco-proteina con ciclodextrina.
SG11202010909RA (en) 2018-05-09 2020-12-30 Regeneron Pharma Anti-msr1 antibodies and methods of use thereof
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
CN115087638B (zh) 2019-12-17 2023-11-24 默沙东公司 Prmt5抑制剂
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
ZA732956B (en) 1974-04-24
HK49079A (en) 1979-07-27
DE2323216A1 (de) 1973-11-29
DE2323216C3 (de) 1978-06-22
JPS4941379A (de) 1974-04-18
GB1428416A (en) 1976-03-17
DE2323216B2 (de) 1977-11-03
NL175917B (nl) 1984-08-16
KE2969A (en) 1979-07-20
CA1003402A (en) 1977-01-11
BE799728A (fr) 1973-09-17
IL42154A0 (en) 1973-07-30
DK133249B (da) 1976-04-12
NL7306979A (de) 1973-11-21
CY1012A (en) 1979-11-23
AU5525273A (en) 1974-11-07
JPS547794B2 (de) 1979-04-10
SU468408A3 (ru) 1975-04-25
FI50711B (de) 1976-03-01
FR2185406A1 (de) 1974-01-04
FR2185406B1 (de) 1976-12-31
FI50711C (fi) 1976-06-10
NL175917C (nl) 1985-01-16
SE378110B (de) 1975-08-18
DK133249C (da) 1976-09-13
US3928326A (en) 1975-12-23

Similar Documents

Publication Publication Date Title
IL42154A (en) Process for the separation of stereoisomeric mixtures of 16a,17a-alkylidenedioxy-pregnane derivatives into their components and components obtained thereby
US3929768A (en) Steroids, processes for their manufacture and preparations containing same
Kingston High performance liquid chromatography of natural products
CA1183835A (en) 4-pregnene-derivatives, a process for their preparation, composition and method for the treatment of inflammatory conditions
CA1338230C (en) Sulfated polysaccharide
HU178088B (en) Process for preparing 3,20-dioxo-4,9-dieno-21-hydroxy-steroids
Enforth et al. A study on liquid-gel partition of steroids and steroid derivatives on lipophilic Sephadex gels
CS195722B2 (en) Process for preparing steriod retinoste
Young et al. Triterpenoid glycosides from Rosa rugosa
Anderson et al. Preparation and evaluation of a hydroxycyclohexyl derivative of sephadex LH-20
D'Auria et al. Isolation and structure elucidation of seven new polyhydroxylated sulfated sterols from the ophiuroid Ophiolepis superba
HU176558B (en) Process for preparing new n-enolesters of steroids
CA1159821A (en) Methylated prostaglandin derivatives
Laatikainen et al. Quantitation of C19O2 and C21O2 steroid mono-and disulfates in human bile
Smith et al. Trimethylsilyl group migration during electron impact and chemical ionization mass spectrometry of the trimethylsilyl ethers of 20‐hydroxy‐5α‐pregnan‐3‐ones and 20‐hydroxy‐4‐pregnen‐3‐ones
GB1495531A (en) 11beta-alkyl steroids of the estrane series
Mulholland et al. Triterpenoids from Turraea holstii
GB1328998A (en) Process of corticosteroids
Rao Synthesis of compounds of potential value in the radioimmunoassay of 17α-ethynylestradiol and mestranol
FANTL et al. Urinary pregn-5-ene-3α, 16α, 20α-triol in adrenal dysfunction
Heller et al. The synthesis of some 21-chloro-16α, 17α-acetonides
Lin et al. High-performance liquid chromatography of steroidal sapogenins
JPS51149258A (en) A process for preparing steroid derivatives
Kupchan et al. Acerotin and acerocin, novel triterpene ester aglycones from the tumour-inhibitory saponins of Acer negundo
Takasaki Steroid Series. VIII. Ozonization of Some Unsaturated Steroid Derivatives.